 Mersana Therapeutics NASDAQ: MRSN releases its next round of earnings this Friday, August 07. Heres Benzingas essential guide to Mersana Therapeuticss Q2 earnings report.Earnings and Revenue Based on managements projections, Mersana Therapeutics analysts modeled for EPS at -0.3 per share on sales of 300.00 thousand. In the same quarter last year, Mersana Therapeutics reported EPS of -0.36 on sales of 202.00 thousand. The analyst consensus estimate would represent a 16.67 increase in the companys earnings. Mersana Therapeuticss reported EPS has stacked up against analyst estimates in the past like this:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate -0.37 -0.38 -0.37 -0.38 EPS Actual -0.35 -0.34 -0.35 -0.36 Revenue Estimate 390.00 K 290.00 K 290.00 K 740.00 K Revenue Actual 11.00 K 42.00 K 844.00 K 202.00 K Stock Performance Over the last 52-week period, shares are up 555.95. Given that these returns are positive, long-term shareholders can be satisfied going into this earnings release.View more earnings on MRSNLooking at these results, shareholders should be feeling unsatisfied with these results.Dont be surprised to see the stock move on comments made during its conference call. Mersana Therapeutics is scheduled to hold the call at 08:00:00 ET and can be accessed here: more from Benzinga Stocks That Hit 52-Week Highs On Wednesday Stocks That Hit 52-Week Highs On TuesdayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 